Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial.

Shouki Bazarbashi,Ahmed Alzahrani,Ali Aljubran,Mahmoud Elshenawy,Ahmed Mostafa Gad,Fatima Maraiki,Noura Alzannan,Tusneem Elhassan,Ahmed Badran

The oncologist（2023）

引用 1|浏览6

暂无评分

摘要

Continuous angiogenesis blockade by adding bevacizumab to the sunitinib on/off regimen for advanced RCC yields significant antitumor activity with manageable increased toxicity.

查看译文

关键词

angiogenesis,bevacizumab,renal cell carcinoma,sunitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要